Resumen

MONTALVO-CASTRO, Rebeca E.  y  SALINAS-JAZMIN, Nohemí. Relationship between the expression of complement inhibitory proteins and therapeutic efficacy of antibodies in breast cancer. Gac. Méd. Méx [online]. 2022, vol.158, n.3, pp.150-159.  Epub 28-Sep-2022. ISSN 2696-1288.  https://doi.org/10.24875/gmm.22000004.

Complement regulatory proteins (mCRPs) CD55, CD46 and CD59 have been proposed as key elements in therapeutic resistance against cancer. mCRP-expressing tumor cells, in addition to hindering trastuzumab, pertuzumab and sacituzumab-govitecan therapeutic activity in breast cancer, can regulate biological processes that promote tumor progression. This review describes the structure of mCRPs and analyzes their expression using transcriptomic databases from breast cancer patients, in addition to collecting information on mCRPs interactions and signaling in tumor cells. Given that mCRPs are relevant targets, several strategies that have been explored for their inhibition and regulation in order to increase therapeutic efficacy and prevent cancer resistance and progression are described.

Palabras llave : Therapeutic antibodies; Breast cancer; Therapeutic resistance; mCRP.